已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Surgical prognosis of lung invasive mucinous and non-mucinous adenocarcinoma: Propensity score matched analysis

医学 腺癌 倾向得分匹配 内科学 肿瘤科 癌症
作者
Jun Oh Lee,Geun Dong Lee,Sehoon Choi,Hyeong Ryul Kim,Yong‐Hee Kim,Dong Kwan Kim,Seung-Il Park,Jae Kwang Yun
出处
期刊:European Journal of Cardio-Thoracic Surgery [Oxford University Press]
卷期号:66 (3)
标识
DOI:10.1093/ejcts/ezae316
摘要

Abstract OBJECTIVES Invasive mucinous adenocarcinoma exhibits distinct prognostic outcomes compared to non-mucinous adenocarcinoma (ADC). This study investigated and compared the clinical outcomes and prognostic factors of invasive mucinous and non-mucinous ADC patients. METHODS This retrospective study included patients who underwent curative surgery for ADC between 2011 and 2021. Patient characteristics were balanced using propensity score matching. Cumulative incidence was analysed to evaluate cancer recurrence incidence, and the Kaplan–Meier method was used to calculate overall survival (OS) for each group. RESULTS A total of 6101 patients were included. After matching, the non-mucinous group and mucinous groups comprised 798 and 408 patients, respectively. The patients in the mucinous group had a lower recurrence incidence than those in the non-mucinous group (P = 0.014). The recurrence incidence in the mucinous group was between those of grades 1 (P = 0.011) and 2 (P = 0.012) and the OS rates were comparable to those of grades 2 (P = 0.6) and 3 (P = 0.2). Multivariable analysis revealed that the maximal standardized uptake value [hazard ratio (HR): 1.13, P = 0.11] and progressed pathological stages (pStage II, HR: 3.9, P = 0.028; pStage III, HR: 8.33, P = 0.038) served as adverse prognostic factors for the mucinous group. CONCLUSIONS Patients with mucinous ADC demonstrated lower recurrence incidence and similar OS rates compared to those with non-mucinous ADC. The recurrence incidence of mucinous ADC was between those of International Association for the Study of Lung Cancer grades 1 and 2, with the OS rates comparable to those of grades 2 and 3. CLINICAL REGISTRATION NUMBER None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mm完成签到 ,获得积分10
刚刚
刚刚
科目三应助张宝采纳,获得10
1秒前
aaaa完成签到,获得积分10
1秒前
Echopotter发布了新的文献求助30
2秒前
3秒前
lqlqhehehe发布了新的文献求助10
3秒前
煮小鱼完成签到 ,获得积分10
4秒前
O已w时o完成签到 ,获得积分10
4秒前
dali发布了新的文献求助10
5秒前
5秒前
terryok发布了新的文献求助10
5秒前
斯文败类应助谦让的小龙采纳,获得10
6秒前
6秒前
文心完成签到,获得积分10
7秒前
小明完成签到,获得积分10
7秒前
7秒前
xxfsx应助科研通管家采纳,获得10
8秒前
浮游应助科研通管家采纳,获得10
8秒前
xxfsx应助科研通管家采纳,获得10
8秒前
科研通AI6应助科研通管家采纳,获得10
8秒前
大龙哥886应助科研通管家采纳,获得10
8秒前
充电宝应助科研通管家采纳,获得10
8秒前
顾矜应助科研通管家采纳,获得10
8秒前
哈基米应助科研通管家采纳,获得20
8秒前
酷波er应助科研通管家采纳,获得10
8秒前
乘风破浪完成签到 ,获得积分0
8秒前
Thien应助科研通管家采纳,获得10
8秒前
浮游应助科研通管家采纳,获得10
9秒前
小蘑菇应助科研通管家采纳,获得10
9秒前
大龙哥886应助科研通管家采纳,获得10
9秒前
Thien应助科研通管家采纳,获得10
9秒前
Gn发布了新的文献求助10
9秒前
9秒前
10秒前
10秒前
Bowingyang发布了新的文献求助10
10秒前
10秒前
彦黄子孙发布了新的文献求助10
11秒前
平凝淡安完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Social Work Ethics Casebook: Cases and Commentary (revised 2nd ed.).. Frederic G. Reamer 1070
The Complete Pro-Guide to the All-New Affinity Studio: The A-to-Z Master Manual: Master Vector, Pixel, & Layout Design: Advanced Techniques for Photo, Designer, and Publisher in the Unified Suite 1000
按地区划分的1,091个公共养老金档案列表 801
The International Law of the Sea (fourth edition) 800
Teacher Wellbeing: A Real Conversation for Teachers and Leaders 600
A Guide to Genetic Counseling, 3rd Edition 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5407331
求助须知:如何正确求助?哪些是违规求助? 4524961
关于积分的说明 14100432
捐赠科研通 4438702
什么是DOI,文献DOI怎么找? 2436460
邀请新用户注册赠送积分活动 1428436
关于科研通互助平台的介绍 1406479